The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Benralizumab: a unique IL-5 inhibitor for severe asthma
|
|---|---|
| Published in |
Journal of Asthma and Allergy, April 2016
|
| DOI | 10.2147/jaa.s78049 |
| Pubmed ID | |
| Authors |
Laren D Tan, Jennifer M Bratt, Dorottya Godor, Samuel Louie, Nicholas J Kenyon |
| Abstract |
The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%-10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic airway inflammation represent approximately 40%-60% of this severe asthmatic population. This form of asthma is often uncontrolled, marked by refractoriness to standard therapy, and shows persistent airway eosinophilia despite glucocorticoid therapy. This paper reviews personalized novel therapies, more specifically benralizumab, a humanized anti-IL-5Rα antibody, while also being the first to provide an algorithm for potential candidates who may benefit from anti-IL-5Rα therapy. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 22% |
| Ecuador | 1 | 11% |
| United Kingdom | 1 | 11% |
| United States | 1 | 11% |
| Unknown | 4 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 4 | 44% |
| Members of the public | 4 | 44% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 76 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 20% |
| Student > Bachelor | 11 | 14% |
| Student > Master | 9 | 12% |
| Other | 9 | 12% |
| Professor | 5 | 7% |
| Other | 14 | 18% |
| Unknown | 13 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 14% |
| Agricultural and Biological Sciences | 8 | 11% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Immunology and Microbiology | 4 | 5% |
| Other | 6 | 8% |
| Unknown | 11 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2022.
All research outputs
#2,157,011
of 24,079,942 outputs
Outputs from Journal of Asthma and Allergy
#52
of 497 outputs
Outputs of similar age
#35,865
of 304,563 outputs
Outputs of similar age from Journal of Asthma and Allergy
#4
of 6 outputs
Altmetric has tracked 24,079,942 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 497 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,563 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.